Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 11/20 | 0.51 |
| ▸ | CDC25B | P30305 | 10/20 | 0.51 |
| ▸ | EBP | Q15125 | 5/20 | 0.50 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410405 | 1.00 | CDC25A (0.51) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL29527487 | 1.00 | CDC25A (0.51) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL332666 | 1.00 | CDC25A (0.51) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL14116734 | 0.87 | CDC25A (0.54) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL14034589 | 0.87 | CDC25A (0.54) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL28161748 | 0.85 | PTPN1 (0.44) | CDC25ACDC25BEBPNPC1L1PTPN1 | |
| SCHEMBL29364678 | 0.83 | CDC25A (0.50) | CDC25ACDC25BEBP | |
| SCHEMBL1470722 | 0.83 | EBP (0.48) | CDC25ACDC25BEBPNPC1L1MEN1 | |
| SCHEMBL1470720 | 0.83 | EBP (0.48) | CDC25ACDC25BEBPNPC1L1MEN1 | |
| SCHEMBL1470719 | 0.83 | EBP (0.48) | CDC25ACDC25BEBPNPC1L1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338841-A1 | Dry Powdered Compositions and Methods and Uses Thereof | NEOZYME INTERNATIONAL, INC. (US) | 2025-11-06 | — | — | US | claimed |
| US-12356985-B2 | Dry powdered compositions and methods and uses thereof | NEOZYME INTERNATIONAL, INC. (US) | 2025-07-15 | — | — | US | claimed |
| US-20240334927-A1 | Dry Powdered Compositions and Methods and Uses Thereof | NEOZYME INTERNATIONAL, INC. (US) | 2024-10-10 | — | — | US | claimed |
| CN-113730386-B | Application of lanolin alkane type triterpene compound | 湖南中医药大学 | 2024-10-01 | — | — | CN | claimed |
| CN-113773193-B | Lanolin alkyl type triterpene compound and application thereof in preparation of anti-inflammatory drugs | 湖南中医药大学 | 2024-09-13 | — | — | CN | claimed |
| CN-118388577-A | Lanostane type triterpene compound and preparation method and application thereof | 广西医科大学 | 2024-07-26 | — | — | CN | claimed |
| CN-117924400-B | Lanostane type triterpene compound, fermentation preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-06-14 | — | — | CN | claimed |
| CN-117924400-A | Lanostane type triterpene compound, fermentation preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-04-26 | — | — | CN | claimed |
| US-11911489-B2 | Saponin-containing compositions for use in textile wipes and methods of use and preparation | SANJEEVITA BY AUDUBON, LLC (US) | 2024-02-27 | — | — | US | claimed |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | STOECKER WILLIAM VAN DOVER (US) | 2024-02-20 | — | — | US | claimed |
| CN-115850060-A | Terpenoid heterodimer in lancang yellow fir, preparation method and pharmaceutical application thereof | 复旦大学 | 2023-03-28 | — | — | CN | claimed |
| EP-4142896-A1 | NON-TOXIC FIRE EXTINGUISHING COMPOSITIONS, DEVICES AND METHODS OF USING SAME | Neozyme Inernational, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| EP-4142522-A1 | DRY POWDERED COMPOSITIONS AND METHODS AND USES THEREOF | Neozyme Inernational, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| CN-113121631-B | Lanostane ganoderma lucidum triterpene compound, preparation method and application | 西北农林科技大学 | 2023-02-03 | — | — | CN | claimed |
| CN-114276398-B | Lanolin alkane type triterpenoid, preparation method and application thereof in preparation of CYP1A2 metabolic enzyme inhibitor | 大连医科大学附属第一医院 | 2022-12-30 | — | — | CN | claimed |
| CN-115531318-A | Anticoagulant drug dabigatran etexilate liposome, preparation method and solid preparation thereof | 山东新时代药业有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115124584-A | Preparation method and application of two lanostane triterpene compounds in ganoderma lucidum | 河南中医药大学 | 2022-09-30 | — | — | CN | claimed |
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | YALE UNIVERSITY | 2022-06-02 | — | — | US | claimed |
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | STOECKER WILLIAM VAN DOVER (US) | 2022-05-05 | — | — | US | claimed |
| CN-114276398-A | Lanolin alkane type triterpenoid, preparation method and application thereof in preparation of CYP1A2 metabolic enzyme inhibitor | 大连医科大学附属第一医院 | 2022-04-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | CAT, CUTA, GPX1 | CDC25A 1531/4885CDC25B 1964/4885EBP 5/4885 |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | CAT, CUTA, GPX1 | CDC25A 1531/4885CDC25B 1964/4885EBP 5/4885 |
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | LSS, CYP46A1, CYP51A1 | CDC25A 4173/4885CDC25B 4799/4885EBP 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.